PHASE II STUDY OF IMATINIB MESYLATE AS THERAPY FOR PATIENTS WITH SYSTEMIC MASTOCYTOSIS

Gain-of-function D816V point mutation within the kinase domain of the transmembrane receptor KIT is found in the great majority of patients with systemic mastocytosis (SM) and is attractive therapeutic target. Twenty patients with SM were enrolled during 2003–2005 in phase II clinical trial with ima...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Vega-Ruiz, Arturo, Cortes, Jorge E., Sever, Matjaz, Manshouri, Taghi, Quintás-Cardama, Alfonso, Luthra, Raja, Kantarjian, Hagop M., Verstovsek, Srdan
Формат: Artigo
Язык:Inglês
Опубликовано: 2009
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4184059/
https://ncbi.nlm.nih.gov/pubmed/19193436
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2008.12.020
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы